Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.
Gavert N, Zwang Y, Weiser R, Greenberg O, Halperin S, Jacobi O, Mallel G, Sandler O, Berger AJ, Stossel E, Rotin D, Grinshpun A, Kamer I, Bar J, Pines G, Saidian D, Bar I, Golan S, Rosenbaum E, Nadu A, Ben-Ami E, Weitzen R, Nechushtan H, Golan T, Brenner B, Nissan A, Margalit O, Hershkovitz D, Lahat G, Straussman R. Gavert N, et al. Nat Cancer. 2022 Feb;3(2):219-231. doi: 10.1038/s43018-021-00325-2. Epub 2022 Feb 10. Nat Cancer. 2022. PMID: 35145327
Perioperative BRAF inhibitors in locally advanced stage III melanoma.
Zippel D, Markel G, Shapira-Frommer R, Ben-Betzalel G, Goitein D, Ben-Ami E, Nissan A, Schachter J, Schneebaum S. Zippel D, et al. J Surg Oncol. 2017 Dec;116(7):856-861. doi: 10.1002/jso.24744. Epub 2017 Jun 26. J Surg Oncol. 2017. PMID: 28650570 Clinical Trial.
Resection of Recurrent Pelvic Soft Tissue Sarcoma: Is the Risk Worth the Reward?
Mor E, Assaf D, Shemla S, Ben-Ami E, Mor-Hadar D, Halfon M, Laks S, Hazzan D, Perelson D, Zippel D, Ben-Yaacov A, Nissan A, Adileh M. Mor E, et al. Among authors: ben ami e. J Surg Res. 2023 Mar;283:914-922. doi: 10.1016/j.jss.2022.10.026. Epub 2022 Dec 8. J Surg Res. 2023. PMID: 36915019
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, Cunningham A, Rodig SJ, Hodi FS, Morgan JA, Merriam P, Wagner AJ, Shapiro GI, George S. Ben-Ami E, et al. Cancer. 2017 Sep 1;123(17):3285-3290. doi: 10.1002/cncr.30738. Epub 2017 Apr 25. Cancer. 2017. PMID: 28440953 Free PMC article. Clinical Trial.
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sänger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Türeci Ö, Forssmann U, Ahmadi T, Şahin U, Jure-Kunkel M, Melero I. Muik A, et al. Cancer Discov. 2022 May 2;12(5):1248-1265. doi: 10.1158/2159-8290.CD-21-1345. Cancer Discov. 2022. PMID: 35176764 Free PMC article. Clinical Trial.
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Apter S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter J. Besser MJ, et al. Clin Cancer Res. 2013 Sep 1;19(17):4792-800. doi: 10.1158/1078-0432.CCR-13-0380. Epub 2013 May 20. Clin Cancer Res. 2013. PMID: 23690483 Clinical Trial.
41 results